CPSE:COLO B

Stock Analysis Report

Executive Summary

Coloplast A/S develops and markets intimate healthcare products and services worldwide.


Snowflake Analysis

Established dividend payer with proven track record.


Similar Companies

Share Price & News

How has Coloplast's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: COLO B has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.9%

COLO B

2.1%

DK Medical Equipment

1.9%

DK Market


1 Year Return

39.2%

COLO B

19.4%

DK Medical Equipment

6.0%

DK Market

Return vs Industry: COLO B exceeded the Danish Medical Equipment industry which returned 17.9% over the past year.

Return vs Market: COLO B exceeded the Danish Market which returned 5.2% over the past year.


Shareholder returns

COLO BIndustryMarket
7 Day-1.9%2.1%1.9%
30 Day9.8%4.1%-4.3%
90 Day21.2%12.7%-4.4%
1 Year42.3%39.2%20.9%19.4%8.2%6.0%
3 Year93.1%78.5%84.7%76.0%36.1%24.7%
5 Year95.9%71.8%106.0%88.5%30.3%13.8%

Price Volatility Vs. Market

How volatile is Coloplast's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Coloplast undervalued compared to its fair value and its price relative to the market?

52.78x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: COLO B (DKK988) is trading above our estimate of fair value (DKK887.09)

Significantly Below Fair Value: COLO B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: COLO B is poor value based on its PE Ratio (52.8x) compared to the Medical Equipment industry average (38.4x).

PE vs Market: COLO B is poor value based on its PE Ratio (52.8x) compared to the Danish market (12.8x).


Price to Earnings Growth Ratio

PEG Ratio: COLO B is poor value based on its PEG Ratio (5.4x)


Price to Book Ratio

PB vs Industry: COLO B is overvalued based on its PB Ratio (38.5x) compared to the DK Medical Equipment industry average (6.4x).


Next Steps

Future Growth

How is Coloplast forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

9.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLO B's forecast earnings growth (9.8% per year) is above the savings rate (-0.3%).

Earnings vs Market: COLO B's earnings (9.8% per year) are forecast to grow slower than the Danish market (12.1% per year).

High Growth Earnings: COLO B's earnings are forecast to grow, but not significantly.

Revenue vs Market: COLO B's revenue (7.9% per year) is forecast to grow faster than the Danish market (6% per year).

High Growth Revenue: COLO B's revenue (7.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: COLO B's Return on Equity is forecast to be very high in 3 years time (63.5%).


Next Steps

Past Performance

How has Coloplast performed over the past 5 years?

16.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: COLO B has high quality earnings.

Growing Profit Margin: COLO B's current net profit margins (21.7%) are lower than last year (23.2%).


Past Earnings Growth Analysis

Earnings Trend: COLO B's earnings have grown by 16.2% per year over the past 5 years.

Accelerating Growth: COLO B's earnings growth over the past year (2%) is below its 5-year average (16.2% per year).

Earnings vs Industry: COLO B earnings growth over the past year (2%) exceeded the Medical Equipment industry -17.2%.


Return on Equity

High ROE: COLO B's Return on Equity (72.9%) is considered outstanding.


Next Steps

Financial Health

How is Coloplast's financial position?


Financial Position Analysis

Short Term Liabilities: COLO B's short term assets (DKK6.4B) do not cover its short term liabilities (DKK6.6B).

Long Term Liabilities: COLO B's short term assets (DKK6.4B) exceed its long term liabilities (DKK1.1B).


Debt to Equity History and Analysis

Debt Level: COLO B's debt to equity ratio (54.8%) is considered high.

Reducing Debt: COLO B's debt to equity ratio has increased from 6.8% to 54.8% over the past 5 years.

Debt Coverage: COLO B's debt is well covered by operating cash flow (154.4%).

Interest Coverage: COLO B earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Coloplast's current dividend yield, its reliability and sustainability?

1.72%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: COLO B's dividend (1.72%) is higher than the bottom 25% of dividend payers in the Danish market (1.7%).

High Dividend: COLO B's dividend (1.72%) is low compared to the top 25% of dividend payers in the Danish market (4.46%).


Stability and Growth of Payments

Stable Dividend: COLO B's dividends per share have been stable in the past 10 years.

Growing Dividend: COLO B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (64.1%), COLO B's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: COLO B's dividends in 3 years are forecast to be covered by earnings (85.7% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Kristian Villumsen (49yo)

1.33s

Tenure

ø17,500,000

Compensation

Mr. Kristian Villumsen has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an Executive Vice President of Chronic Care at Coloplast A/S since July  ...


CEO Compensation Analysis

Compensation vs Market: Kristian's total compensation ($USD2.55M) is about average for companies of similar size in the Danish market ($USD3.18M).

Compensation vs Earnings: Kristian's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kristian Villumsen
President & CEO1.33yrsø17.50m0.043% DKK89.6m
Anders Lonning-Skovgaard
Executive VP & CFO5.75yrsø9.90mno data
Allan Rasmussen
Executive Vice President of Global Operations5.75yrsø9.50m0.00015% DKK315.0k
Paul Marcun
Executive Vice President of Chronic Care1.25yrsø8.90mno data
Thomas Barfod
Senior Controller & Director13.33yrsø450.00k0.0019% DKK3.9m
Ellen Bjurgert
Vice President of Investor Relations3.5yrsno datano data
Dennis Kaysen
Director of Corporate Communicationsno datano datano data
Nicolai Andersen
Senior Vice President of Wound Careno datano datano data
Alain Morvan
Senior Vice President of Sales Europe8yrsno datano data
Oliver Johansen
Senior Vice President of Global R&D7.33yrsno datano data

5.8yrs

Average Tenure

49yo

Average Age

Experienced Management: COLO B's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Barfod
Senior Controller & Director13.33yrsø450.00k0.0019% DKK3.9m
Carsten Hellmann
Independent Director2.33yrsø634.00k0.0028% DKK5.9m
Jørgen Tang-Jensen
Independent Director12.33yrsø767.00k0.0034% DKK7.2m
Lars Rasmussen
Chairman of the Board1.33yrsø20.56m0.098% DKK204.9m
Niels Louis-Hansen
Deputy Chairmanno dataø910.00k22.12% DKK46.5b
Jette Nygaard-Andersen
Independent Director4.33yrsø532.00kno data
Birgitte Nielsen
Independent Director4.33yrsø634.00k0.000080% DKK168.0k
Nikolaj Gundersen
Director2.25yrsø369.00k0.000070% DKK147.0k
Roland Pedersen
Director2.25yrsø369.00k0.00070% DKK1.5m

3.3yrs

Average Tenure

56yo

Average Age

Experienced Board: COLO B's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Coloplast A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Coloplast A/S
  • Ticker: COLO B
  • Exchange: CPSE
  • Founded: 1954
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: ø209.991b
  • Shares outstanding: 212.54m
  • Website: https://www.coloplast.com

Number of Employees


Location

  • Coloplast A/S
  • Holtedam 1-3
  • Humlebæk
  • 3050
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLPB.FOTCPK (Pink Sheets LLC)YesClass B SharesUSUSDMar 1993
COLO BCPSE (OMX Nordic Exchange Copenhagen)YesClass B SharesDKDKKMar 1993
CBHDDB (Deutsche Boerse AG)YesClass B SharesDEEURMar 1993
COLOBCBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBDKKMar 1993
0QBOLSE (London Stock Exchange)YesClass B SharesGBDKKMar 1993
COLOBSWX (SIX Swiss Exchange)YesClass B SharesCHCHFMar 1993
COLOWBAG (Wiener Boerse AG)YesClass B SharesATEURMar 1993
0QBO NBMV (Bolsa Mexicana de Valores)YesClass B SharesMXMXNMar 1993
CLPB.YOTCPK (Pink Sheets LLC)UNSPONSORD ADRUSUSDNov 2010

Biography

Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit to individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catherisation for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies; and directly to users. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/08 01:15
End of Day Share Price2020/04/07 00:00
Earnings2019/12/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.